Cultural and Social Considerations in Clinical Trials Enrollment - - PowerPoint PPT Presentation

▶

Dec 18, 2023 36 likes •157 views

Cultural and Social Considerations in Clinical Trials Enrollment and Outreach Moon S. Chen, Jr., Ph.D., M.P.H. Associate Director for Cancer Control UC Davis Comprehensive Cancer Center July 25, 2014 ACKNOWLEDGMENTS The views expressed are

SLIDE 1

Cultural and Social Considerations in Clinical Trials Enrollment and Outreach

Moon S. Chen, Jr., Ph.D., M.P.H. Associate Director for Cancer Control UC Davis Comprehensive Cancer Center July 25, 2014

SLIDE 2

ACKNOWLEDGMENTS

The views expressed are those of the presenter and do not necessarily represent the views of the NIH. However, I am grateful for the support provided through the NCI to AANCART (U54 CA153499) and the NIMHD to EMPaCT (U24MD006970).

Slides created by: Julie Dang, MPH, CHES

SLIDE 3

Objectives of Presentation

Highlight PROBLEMS we are trying to solve Identify provider and patient PERSPECTIVES with respect to participation in clinical trials Propose a PARADIGM that integrates both perspectives to mitigate the problem

SLIDE 4

Problems

SLIDE 5

Adults vs Children in Clinical Trials

ADULTS CHILDREN Black 1.3% 10.4% Hispanic 1.3% 11.6% AIAN 2.5%

1.7%

Other
4.7%

TOTAL <5% 60%

Chen MS Jr., et al. Twenty years post-NIH Revitalization Act: EMPaCT laying the groundwork for improving minority participation in clinical trial accrual. Cancer 2014; 120 (Suppl 7): 1091-6.

SLIDE 6

Projected Cases of All Invasive Cancers in the United States by Race and Origin

142% increased incidence for Hispanics of any race 132% increased incidence for Asian/Pacific Islanders 101% increased incidence for multiracial 76% increased incidence for American Indian /Alaska Natives 64% increased incidence for Blacks

Smith B, Smith GL, et al. Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation. J Clin Oncol 27 by American Society of Clinical Oncology. 2009

SLIDE 7

Perspectives

SLIDE 8

Provider’s Perspective

Providers are the most influential factor in patient enrollment in clinical trials

SLIDE 9

Patient’s Perspective

DEMOGRAPHICS SOCIAL CULTURAL

AGE VALUES HERITAGE COMMUNICABILITY

SLIDE 10

PARADIGM

TOOLS TRUSTWORTHINESS TANGIBLE BENEFITS TIME TRUST

SLIDE 11

DOES THIS WORK?

Brown M, Moyer A. Predictors of awareness of clinical trials and feelings about the use of medical information for research in a nationally representative US

sample. Ethnic Health.

2010;15:223-226. Tong EK, Fung LC, Stewart SL, Paterniti DA, Dang JHT, Chen MS Jr. Impact of a biospecimen collection seminar on willingness to donate biospecimens among Chinese Americans: Results from a randomized, controlled community-based

trial. Cancer Epidemiol

Biomarkers, & Prevention 2014 Dang JHT, Rodriguez EM, Luque JS, Erwin DO, Meade CD, Chen MS Jr. Engaging diverse populations about biospecimen donation for cancer research. Journal of Community Genetics 2014

Yes, minorities are willing to participate in health research

Yes, TRUST is the key

SLIDE 12